One Stop Systems Pops on Q2 Numbers
One Stop Systems, Inc. (NASDAQ: OSS), shares began Thursday sharply higher. The company, a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML), autonomy and sensor processing at the edge, reported results for the second quarter ended June 30, 2025.
“The performance of our OSS segment in the first half of the year demonstrates the meaningful progress we have made repositioning the Company for sustained growth," stated CEO Mike Knowles.
“We are successfully converting our large, multi-year pipeline into orders, while making strategic investments in R&D. Year-to-date, our OSS segment has generated one of the highest levels of bookings in our history, totaling $25.4 million and representing a book-to-bill ratio of 2.3x. This strong start to 2025 underscores the solid foundation we have built as we capitalize on increasing demand from both defense and commercial customers for our rugged, enterprise-class compute solutions.”
Consolidated revenue increased 6.9% to $14.1 million, from $13.2 million in the second quarter of 2024.
The Company reported a net loss of $2.0 million, or $(0.09) per share for the three months ended June 30, 2025, as compared to a net loss of $2.3 million, or $(0.11) per share, in the prior year period. The Company reported a non-GAAP net loss of $1.5 million, or $(0.07) per share, compared to non-GAAP net loss of $1.8 million, or $(0.09) per share.
OSS shares hiked 66 cents, or 13.4%, to $5.58.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


